KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Receivables (2016 - 2025)

Pfizer (PFE) has disclosed Receivables for 17 consecutive years, with $11.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 3.59% to $11.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 billion, a 3.59% increase, with the full-year FY2025 number at $11.9 billion, up 3.59% from a year prior.
  • Receivables was $11.9 billion for Q4 2025 at Pfizer, down from $14.3 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $16.2 billion in Q4 2022 to a low of $10.2 billion in Q3 2023.
  • A 5-year average of $12.2 billion and a median of $11.7 billion in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: surged 39.98% in 2022, then plummeted 33.68% in 2023.
  • Pfizer's Receivables stood at $11.5 billion in 2021, then fell by 5.03% to $11.0 billion in 2022, then increased by 5.61% to $11.6 billion in 2023, then dropped by 0.89% to $11.5 billion in 2024, then increased by 3.59% to $11.9 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Receivables are $11.9 billion (Q4 2025), $14.3 billion (Q3 2025), and $12.1 billion (Q2 2025).